{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:45:38Z","timestamp":1774532738837,"version":"3.50.1"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Danish Council for Independent Research | Natural Sciences","award":["DFF-4002-00502"],"award-info":[{"award-number":["DFF-4002-00502"]}]},{"name":"Danish Council for Independent Research | Natural Sciences","award":["DFF-7014-00192B"],"award-info":[{"award-number":["DFF-7014-00192B"]}]},{"name":"Medical Sciences","award":["DFF \u2013 4004-00309"],"award-info":[{"award-number":["DFF \u2013 4004-00309"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.neuropharm.2019.02.030","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T02:48:26Z","timestamp":1551062906000},"page":"107548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies"],"prefix":"10.1016","volume":"161","author":[{"given":"Talia","family":"Zeppelin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy Kate","family":"Ladefoged","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Sinning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-1562","authenticated-orcid":false,"given":"Birgit","family":"Schi\u00f8tt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.02.030_bib1","article-title":"Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics","author":"Abramyan","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib2","doi-asserted-by":"crossref","first-page":"10484","DOI":"10.1021\/bi700429z","article-title":"Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching","volume":"46","author":"Adkins","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib3","article-title":"Brexpiprazole in the treatment of major depressive disorder","volume":"9","author":"Al Shirawi","year":"2017","journal-title":"Clin. Med. Insights Ther."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib4","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1042\/BST20160217","article-title":"Transporter oligomerization: form and function","volume":"44","author":"Alguel","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib6","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1074\/jbc.M113.531632","article-title":"Single molecule analysis reveals coexistence of stable serotonin transporter monomers and oligomers in the live cell plasma membrane","volume":"289","author":"Anderluh","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib7","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1039\/b903035m","article-title":"Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters","author":"Andersen","year":"2009","journal-title":"Chem. Commun."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib8","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acschemneuro.5b00225","article-title":"Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter","volume":"6","author":"Andersen","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib9","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1074\/jbc.M109.072587","article-title":"Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter","volume":"285","author":"Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib10","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1038\/srep15650","article-title":"Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter","volume":"5","author":"Andersen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib11","doi-asserted-by":"crossref","first-page":"12137","DOI":"10.1073\/pnas.1103060108","article-title":"Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters","volume":"108","author":"Andersen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/mol.113.091249","article-title":"Molecular basis for selective serotonin re-uptake inhibition by the antidepressant agent fluoxetine (Prozac)","volume":"85","author":"Andersen","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib13","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M806907200","article-title":"Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in the recognition of citalopram and tricyclic antidepressants","volume":"284","author":"Andersen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib14","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.1523\/JNEUROSCI.22-19-08370.2002","article-title":"Accessibility and conformational coupling in serotonin transporter predicted internal domains","volume":"22","author":"Androutsellis-Theotokis","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/jpet.108.142315","article-title":"Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism","volume":"327","author":"Apparsundaram","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib16","doi-asserted-by":"crossref","first-page":"9709","DOI":"10.1021\/jm4014136","article-title":"Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites","volume":"56","author":"Banala","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib17","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0076-6879(98)96035-9","article-title":"Structural determinants of neurotransmitter transport using cross-species chimeras: studies on serotonin transporter","volume":"296","author":"Barker","year":"1998","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib19","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1523\/JNEUROSCI.19-12-04705.1999","article-title":"Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter","volume":"19","author":"Barker","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib20","doi-asserted-by":"crossref","first-page":"19459","DOI":"10.1074\/jbc.273.31.19459","article-title":"High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis","volume":"273","author":"Barker","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eurpsy.2007.11.001","article-title":"Prescribing patterns of antidepressants in Europe: results from the factors influencing depression endpoints research (FINDER) study","volume":"23","author":"Bauer","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1124\/mol.106.026120","article-title":"A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter\/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function","volume":"70","author":"Beuming","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib23","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.1074\/jbc.M114.573477","article-title":"A dualistic conformational response to substrate binding in the human serotonin transporter reveals a high affinity state for serotonin","volume":"290","author":"Bjerregaard","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/354066a0","article-title":"Cloning and expression of a functional serotonin transporter from rat brain","volume":"354","author":"Blakely","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib25","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/bph.13030","article-title":"Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues","volume":"172","author":"Bonano","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib26","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.bbamem.2016.07.005","article-title":"The lipid habitats of neurotransmitter receptors in brain","volume":"1858","author":"Borroni","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","article-title":"Paroxetine: a review","volume":"7","author":"Bourin","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib28","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.bmc.2016.04.039","article-title":"Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter","volume":"24","author":"Brink\u00f8","year":"2016","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib29","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1074\/jbc.270.16.9197","article-title":"Antipeptide antibodies confirm the topology of the human norepinephrine transporter","volume":"270","author":"Br\u00fcss","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib30","doi-asserted-by":"crossref","first-page":"11642","DOI":"10.1073\/pnas.1220552110","article-title":"Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate","volume":"110","author":"Buchmayer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15171\/apb.2017.061","article-title":"Chirality of modern antidepressants: an overview","volume":"7","author":"Budau","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib32","doi-asserted-by":"crossref","first-page":"18524","DOI":"10.1074\/jbc.M112.343681","article-title":"The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters","volume":"287","author":"Bulling","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib33","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1021\/ja076403h","article-title":"Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation","volume":"130","author":"Celik","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1471-4159.2004.02835.x","article-title":"Characterization of an allosteric citalopram-binding site at the serotonin transporter","volume":"92","author":"Chen","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.euroneuro.2004.08.008","article-title":"The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors","volume":"15","author":"Chen","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib36","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.1074\/jbc.273.20.12675","article-title":"Determination of external loop topology in the serotonin transporter by site-directed chemical labeling","volume":"273","author":"Chen","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib37","doi-asserted-by":"crossref","first-page":"28321","DOI":"10.1074\/jbc.272.45.28321","article-title":"The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding","volume":"272","author":"Chen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jcc.20222","article-title":"Importance of accurate charges in molecular docking: quantum mechanical\/molecular mechanical (QM\/MM) approach","volume":"26","author":"Cho","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nsmb.1854","article-title":"Ion\/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters","volume":"17","author":"Claxton","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41594-018-0026-8","article-title":"Structural basis for recognition of diverse antidepressants by the human serotonin transporter","volume":"25","author":"Coleman","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nature17629","article-title":"X-ray structures and mechanism of the human serotonin transporter","volume":"532","author":"Coleman","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.bjp.0701325","article-title":"Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine","volume":"121","author":"Crespi","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib43","doi-asserted-by":"crossref","first-page":"23789","DOI":"10.1038\/srep23789","article-title":"Mechanism of paroxetine (paxil) inhibition of the serotonin transporter","volume":"6","author":"Davis","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-3565(25)31549-1","article-title":"Chemical-release of dopamine from striatal homogenates - evidence for an exchange diffusion-model","volume":"208","author":"Fischer","year":"1979","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbabio.2010.10.014","article-title":"The structural basis of secondary active transport mechanisms","volume":"1807","author":"Forrest","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib46","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1471-4159.2008.05262.x","article-title":"Phorbol ester induced trafficking\u2010independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol","volume":"105","author":"Foster","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib47","doi-asserted-by":"crossref","first-page":"17836","DOI":"10.1523\/JNEUROSCI.3284-13.2013","article-title":"Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton","volume":"33","author":"Gabriel","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00894-011-1133-1","article-title":"Substrate binding and translocation of the serotonin transporter studied by docking and molecular dynamics simulations","volume":"18","author":"Gabrielsen","year":"2012","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib50","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.1975955","article-title":"Cloning and expression of a rat-brain GABA transporter","volume":"249","author":"Guastella","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib51","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/acs.jpcb.6b09876","article-title":"Effect of dimerization on the dynamics of neurotransmitter:sodium symporters","volume":"121","author":"Gur","year":"2017","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","article-title":"Brain serotonin transporter binding in non-depressed patients with Parkinson's disease","volume":"14","author":"Guttman","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib53","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1074\/jbc.M505055200","article-title":"Tyr95 and Ile172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high-affinity recognition of antidepressants","volume":"281","author":"Henry","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: from monoamines to glutamate","volume":"23","author":"Hillhouse","year":"2015","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib55","doi-asserted-by":"crossref","first-page":"32616","DOI":"10.1074\/jbc.M110.150565","article-title":"Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding","volume":"285","author":"Hong","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","article-title":"Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone","volume":"510","author":"Hughes","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199403001-00004","article-title":"Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)","volume":"9","author":"Hyttel","year":"1994","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01244820","article-title":"The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer","volume":"88","author":"Hyttel","year":"1992","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib59","doi-asserted-by":"crossref","first-page":"29441","DOI":"10.1074\/jbc.M704456200","article-title":"Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter","volume":"282","author":"Jacobs","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/211969a0","article-title":"Simple allosteric model for membrane pumps","volume":"211","author":"Jardetzky","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib61","doi-asserted-by":"crossref","first-page":"19315","DOI":"10.1074\/jbc.M311172200","article-title":"Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated internalization","volume":"279","author":"Jayanthi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006229","article-title":"Dopamine transporter oligomerization involves the scaffold domain, but spares the bundle domain","volume":"14","author":"Jayaraman","year":"2018","journal-title":"PLoS Comp. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","article-title":"Understanding the pathophysiology of depression: from monoamines to the neurogenesis hypothesis model - are we there yet?","volume":"341","author":"Jesulola","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(86)90615-1","article-title":"Effects of the enantiomers of MDA, MDMA and related analogs on [H-3] serotonin and [H-3] dopamine release from superfused rat-brain slices","volume":"132","author":"Johnson","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cmdc.200600242","article-title":"Homology modeling of the serotonin transporter: insights into the primary escitalopram-binding site","volume":"2","author":"J\u00f8rgensen","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib66","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/prot.22178","article-title":"Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies","volume":"74","author":"Kaufmann","year":"2009","journal-title":"Proteins: Struct. Funct. Bioinform."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib67","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nsmb.2816","article-title":"Conformational dynamics of ligand-dependent alternating access in LeuT","volume":"21","author":"Kazmier","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib68","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0021-9258(19)68170-6","article-title":"Coupling of transmembrane proton gradients to platelet serotonin transport","volume":"257","author":"Keyes","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib69","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/prot.24792","article-title":"Computational modeling of the N-terminus of the human dopamine transporter and its interaction with PIP2-containing membranes","volume":"83","author":"Khelashvili","year":"2015","journal-title":"Proteins: Struct. Funct. Bioinform."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063635","article-title":"Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations","volume":"8","author":"Kolds\u00f8","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/cn300148r","article-title":"Comparative modeling of the human monoamine transporters: similarities in substrate binding","volume":"4","author":"Kolds\u00f8","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2015.00208","article-title":"Insights to ligand binding to the monoamine transporters \u2013 from homology modeling to LeuBAT and dDAT","volume":"6","author":"Kolds\u00f8","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002246","article-title":"Unbiased simulations reveal the inward-facing conformation of the human serotonin transporter and Na+ ion release","volume":"7","author":"Kolds\u00f8","year":"2011","journal-title":"PLoS Comp. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib74","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/ja906923j","article-title":"The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations","volume":"132","author":"Kolds\u00f8","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00702-007-0826-1","article-title":"Pharmacological models of ADHD","volume":"115","author":"Kostrzewa","year":"2008","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bph.13411","article-title":"Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the 5-HT transporter","volume":"173","author":"Larsen","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib78","doi-asserted-by":"crossref","first-page":"42147","DOI":"10.1074\/jbc.M405579200","article-title":"The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors","volume":"279","author":"Larsen","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib79","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1074\/jbc.M117.809046","article-title":"Cholesterol binding to a conserved site modulates conformation, pharmacology and transport kinetics of the human serotonin transporter","volume":"293","author":"Laursen","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib80","first-page":"167","article-title":"Treatment-resistant depression","volume":"80","author":"Little","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib81","doi-asserted-by":"crossref","first-page":"38770","DOI":"10.1074\/jbc.M400831200","article-title":"Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin","volume":"279","author":"Magnani","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib82","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(95)00273-9","article-title":"Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin","volume":"57","author":"Mash","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004850-200505000-00002","article-title":"Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder","volume":"20","author":"Moore","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1471-4159.2001.00587.x","article-title":"Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants","volume":"79","author":"Mortensen","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib85","first-page":"e3","volume":"vol. 1","author":"Nicolson","year":"2013"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib86","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/350350a0","article-title":"Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter","volume":"350","author":"Pacholczyk","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nature12533","article-title":"X-ray structure of dopamine transporter elucidates antidepressant mechanism","volume":"503","author":"Penmatsa","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/nsmb.3029","article-title":"X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine","volume":"22","author":"Penmatsa","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/neu.2017.39","article-title":"A brief history of antidepressant drug development: from tricyclics to beyond ketamine","volume":"30","author":"Pereira","year":"2018","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib90","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1038\/s41598-018-22912-7","article-title":"Dimer interface of the human serotonin transporter and effect of the membrane composition","volume":"8","author":"Periole","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature08147","article-title":"Emerging roles for lipids in shaping membrane-protein function","volume":"459","author":"Phillips","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.03.055","article-title":"Allosteric effects of R-and S-citalopram on the human 5-HT transporter: evidence for distinct high-and low-affinity binding sites","volume":"567","author":"Plenge","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(85)90314-0","article-title":"Antidepressive drugs can change the affinity of [3H] imipramine and [3H] paroxetine binding to platelet and neuronal membranes","volume":"119","author":"Plenge","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0922-4106(05)80025-2","article-title":"Affinity modulation of [3H] imipramine, [3H] paroxetine and [3H] citalopram binding to the 5-HT transporter from brain and platelets","volume":"206","author":"Plenge","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib95","doi-asserted-by":"crossref","first-page":"39316","DOI":"10.1074\/jbc.M112.371765","article-title":"Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter","volume":"287","author":"Plenge","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00894-006-0154-7","article-title":"An overview of halogen bonding","volume":"13","author":"Politzer","year":"2007","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0031-6997(25)06842-5","article-title":"100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug","volume":"47","author":"Popik","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib98","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/WNR.0b013e328362066d","article-title":"Antidepressive effect of paroxetine in a rat model: upregulating expression of serotonin and norepinephrine transporter","volume":"24","author":"Qiu","year":"2013","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib99","doi-asserted-by":"crossref","first-page":"26444","DOI":"10.1074\/jbc.M602438200","article-title":"State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter:sodium symporter from Fusobacterium nucleatum","volume":"281","author":"Quick","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib100","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1021\/acschembio.7b00338","article-title":"Mapping the binding site for escitalopram and paroxetine in the human serotonin transporter using genetically encoded photo-cross-linkers","volume":"12","author":"Rannversson","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib101","doi-asserted-by":"crossref","first-page":"11261","DOI":"10.1038\/ncomms11261","article-title":"Genetically encoded photocrosslinkers locate the high-affinity binding site of antidepressant drugs in the human serotonin transporter","volume":"7","author":"Rannversson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib102","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1017\/S1461145712001605","article-title":"Multi-modality: a new approach for the treatment of major depressive disorder","volume":"16","author":"Richelson","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib103","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/S0021-9258(17)40535-7","article-title":"Active-transport of 5-hydroxytryptamine by plasma-membrane vesicles isolated from human-blood platelets","volume":"252","author":"Rudnick","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00424-013-1410-1","article-title":"The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction","volume":"466","author":"Rudnick","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib105","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1021\/bi00615a021","article-title":"Platelet 5-hydroxytryptamine transport, an electroneutral mechanism coupled to potassium","volume":"17","author":"Rudnick","year":"1978","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib106","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of ecstasy [3,4-methylenedioxy-methamphetamine (MDMA)] - serotonin transporters are targets for MDMA-induced serotonin release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib107","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1021\/bi00144a010","article-title":"Para-chloroamphetamine induces serotonin release through serotonin transporters","volume":"31","author":"Rudnick","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib108","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/bph.13043","article-title":"Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues","volume":"172","author":"Sakloth","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/mol.115.101394","article-title":"Binding mode selection determines the action of ecstasy homologs at monoamine transporters","volume":"89","author":"Sandtner","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib111","doi-asserted-by":"crossref","first-page":"212290","DOI":"10.7573\/dic.212290","article-title":"Antidepressant efficacy and side-effect burden: a quick guide for clinicians","volume":"4","author":"Santarsieri","year":"2015","journal-title":"Drugs Context"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib112","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1124\/mol.110.067538","article-title":"The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter","volume":"78","author":"Sarker","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib113","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1074\/jbc.M111.304261","article-title":"Unifying concept of serotonin transporter-associated currents","volume":"287","author":"Schicker","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.156.3771.21","article-title":"Biogenic amines and emotion","volume":"156","author":"Schildkraut","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib115","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1074\/jbc.M209824200","article-title":"Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate","volume":"278","author":"Schwartz","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib116","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/minf.201300013","article-title":"Probing the selectivity of monoamine transporter substrates by means of molecular modeling","volume":"32","author":"Seddik","year":"2013","journal-title":"Mol. Inform."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib117","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib118","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.113.088922","article-title":"Binding of mazindol and analogs to the human serotonin and dopamine transporters","volume":"85","author":"Severinsen","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib119","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1021\/cn300040f","article-title":"Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters","volume":"3","author":"Severinsen","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0740-5472(94)90049-3","article-title":"A preliminary investigation of ibogaine: case reports and recommendations for further study","volume":"11","author":"Sheppard","year":"1994","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib121","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib122","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004697","article-title":"Membrane organization and lipid rafts","volume":"3","author":"Simons","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib123","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nature06038","article-title":"Antidepressant binding site in a bacterial homologue of neurotransmitter transporters","volume":"448","author":"Singh","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib124","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1074\/jbc.M109.045401","article-title":"Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter","volume":"285","author":"Sinning","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02805969","article-title":"Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine","volume":"127","author":"Staley","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02245936","article-title":"Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity","volume":"118","author":"Sweetnam","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib127","doi-asserted-by":"crossref","first-page":"43694","DOI":"10.1074\/jbc.M112.342212","article-title":"Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket","volume":"287","author":"S\u00f8rensen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib128","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1523\/JNEUROSCI.0440-09.2009","article-title":"Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes","volume":"29","author":"Tavoulari","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib129","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1074\/jbc.M115.692012","article-title":"Two Na+ sites control conformational change in a neurotransmitter transporter homolog","volume":"291","author":"Tavoulari","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.bmcl.2016.12.037","article-title":"X-ray structure based evaluation of analogs of citalopram: compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT","volume":"27","author":"Topiol","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib131","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib132","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0026-895X(25)08574-8","article-title":"Biogenic-amine flux mediated by cloned transporters stably expressed in cultured-cell lines - amphetamine specificity for inhibition and efflux","volume":"47","author":"Wall","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib133","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1126\/science.1232807","article-title":"Structural basis for molecular recognition at serotonin receptors","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib134","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nature14431","article-title":"Neurotransmitter and psychostimulant recognition by the dopamine transporter","volume":"521","author":"Wang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib135","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(82)90333-8","article-title":"Serotonin modulates the dissociation of [3H]imipramine from human platelet recognition sites","volume":"86","author":"Wennogle","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib136","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1074\/jbc.M111.304873","article-title":"Probing binding pocket of serotonin transporter by single molecular force spectroscopy on living cells","volume":"287","author":"Wildling","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib137","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"The discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"Wong","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib138","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1039\/C5CP05771J","article-title":"Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study","volume":"18","author":"Xue","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib139","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/acschemneuro.7b00490","article-title":"What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation","volume":"9","author":"Xue","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature03978","article-title":"Crystal structure of a bacterial homologue of Na+\/Cl--dependent neurotransmitter transporters","volume":"437","author":"Yamashita","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005907","article-title":"A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition","volume":"14","author":"Zeppelin","year":"2018","journal-title":"PLoS Comp. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib142","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1021\/jm1005034","article-title":"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters","volume":"53","author":"Zhang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib143","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nature09057","article-title":"Single-molecule dynamics of gating in a neurotransmitter transporter homologue","volume":"465","author":"Zhao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib144","doi-asserted-by":"crossref","first-page":"26883","DOI":"10.1038\/srep26883","article-title":"Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib145","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.1147614","article-title":"LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake","volume":"317","author":"Zhou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.030_bib146","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nsmb.1602","article-title":"Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures","volume":"16","author":"Zhou","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.030_bib147","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/anie.201508755","article-title":"Nanopharmacological force sensing to reveal allosteric coupling in transporter binding sites","volume":"55","author":"Zhu","year":"2016","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:59:00Z","timestamp":1758437940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819300693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":147,"alternative-id":["S0028390819300693"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.030","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107548"}}